Gilead’s golden ticket leaves rivals in its wake
After just five weeks on the US market, Gilead Sciences’ promising hepatitis C drug Sovaldi has already distanced itself from its nearest rivals.
by Nikolaj Vorre
Gilead Sciences’ newest drug Sovaldi (sofosbuvir) has been off to a flying start and is already on the way to living up to the high expectations for the product.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Gilead could be sitting on biggest blockbuster ever
For abonnenter
Major investor: Breakthrough in hepatitis battle
For abonnenter
